Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
Project Summary/Abstract
Animal models have become an increasingly valuable tool for biomedical research. Animal models are
particularly relevant to the understanding of cystic fibrosis (CF), where they are used extensively to
characterize CFTR expression and function and investigate the pathophysiology of cystic fibrosis. Furthermore,
animal models are critical to evaluating the effectiveness of novel therapies. The purpose of Core B is to
support the research of numerous P30 investigators that involves animal models, and the innovative assays
available to characterize them.
Core B carries out three main functions as outlined in the Specific Aims. First, Core B breeds, genotypes, and
distributes diverse CF relevant animal models. It provides CF models of mouse, rat, ferret and pig to dozens of
local, national, and international P30 investigators. Second, the Core aids in the generation and procurement
of relevant animal models required by P30 investigators. The Core helps generate new animal models using
cutting edge recombinant technology, including the novel rat model centered at UAB and more recently
humanized versions of this species (designated a National Core Resource). In addition, the Core acquires
available animals needed by P30 investigators, such as the CF ferret and pig models. In this way, the Core
helps investigators develop and characterize innovative animal models that can be used to expand the current
body of CF research. Third, Core B has developed numerous endpoint measures to assess CFTR function,
epithelial physiology, preclinical endpoints, and biospecimen analysis in CF animal models. The endpoint
assays conducted by the core include: extensive CFTR physiological outcome measures; assays of epithelial
function; state-of-the-art imaging modalities of the GI and respiratory tract (including ultrasound, micro-CT, and
micro-optical coherence tomography (a second National Resource, see Core A); physiological assays such as
Flexivent lung function, plethysmography, and cough monitoring; survival bronchoscopy; and techniques for
drug delivery and monitoring. These cutting-edge endpoint analyses supported by Core B help to uncover
disease mechanisms and pathways, and to elucidate clinically relevant findings.
Core B provides significant resources and technical expertise that greatly augment efforts of P30 investigators.
The efforts put forth by Core B foster the sharing of ideas and promote collaboration among investigators.
Furthermore, the Core contributes to significant cost savings by providing animal models, electrophysiologic
equipment, expensive imaging modalities, small animal bronchoscopy and tissue/specimen processing, and
resources that are shared among many investigators without the need to duplicate the same capabilities in
multiple laboratories. In these ways, P30 Core B is indispensable for the research priorities delineated by the
overall UAB P30, including studies of CFTR cellular biology, tissue pathogenesis, and clinical translation.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-April-2007
Project End Date
30-April-2028
Budget Start Date
01-May-2024
Budget End Date
30-April-2025
Project Funding Information for 2024
Total Funding
$285,000
Direct Costs
$191,919
Indirect Costs
$93,081
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Diabetes and Digestive and Kidney Diseases
$285,000
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P30DK072482-18 8671
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30DK072482-18 8671
Patents
No Patents information available for 5P30DK072482-18 8671
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30DK072482-18 8671
Clinical Studies
No Clinical Studies information available for 5P30DK072482-18 8671
News and More
Related News Releases
No news release information available for 5P30DK072482-18 8671
History
No Historical information available for 5P30DK072482-18 8671
Similar Projects
No Similar Projects information available for 5P30DK072482-18 8671